Agilent's Resource Center
Analysis of Camelid Single-Domain Antibodies Using Agilent AdvanceBio SEC 120 Å 1.9 µm and AdvanceBio HIC Columns
Achieve high-resolution nanobody aggregate and fragment characterization with sub-2µm SEC UV and native LC/MS detection, and resolve important post translational modifications with non-denaturing HIC.
Mass Spectrometric Characterization of Antibody-siRNA Conjugates using the Agilent 6545XT AdvanceBio LC/Q-TOF
Denaturing (reversed-phase) and non-denaturing (size exclusion) analyses of novel siRNA conjugated monoclonal antibodies by LC/MS
Download the Application Note
Elevate Your mAb Aggregate Analysis: High-resolution SEC with the Agilent 1290 Infinity II Bio LC System
How to optimize your ultra-high performance size exclusion separations, using biocompatible UHPLC instrumentation with attention to minimizing extra-column dead volume.
Download the Application Note
An Improved Workflow for Profiling and Quantitation of Sialic Acids in Biotherapeutics
This work highlights a newly-released Agilent workflow for profiling and quantitation of sialic acids in biotherapeutic glycoproteins. This new workflow includes all the reagents necessary for sample preparation of sialic acids and also features a qualitative Sialic Acid Reference Panel ase well as quantitative NANA and NGNA standards.
Download the Application Note
Analysis of a Synthetic Peptide and Its Impurities Using mass spectrometry compatible mobile phases with an Agilent AdvanceBio Peptide Plus column
The benefits of using a charged-surface modified C18 reversed-phase column for improved performance and peak shape of a synthetic peptide using LC/MS methodology.
Download the Application Note
Seamless Method Transfer to the Agilent 1290 Infinity II Bio LC System Peptide-mapping analysis shows excellent performance and high method compatibility compared to the Agilent 1290 Infinity II LC System
Transitioning validated methods between instruments is sometimes a challenge. Using a peptide mapping example, we demonstrate exceptional data consistency between the Agilent 1290 Infinity II LC and the biocompatible Agilent 1290 Infinity II Bio LC.
How Shallow Can You Go? Refining charge variant analysis of mAbs with the Agilent 1290 Infinity II Bio LC System
Excellent rentention time and peak area reproducibility are possible even with highly challenging shallow gradients for ion exchange chromatography.
Improved Lifetime of Bio-Monolith Protein A Columns for Titer Determination
Learn how to increase column lifetime with an improved monolithic affinity chromatography column designed for rapid screening of monoclonal antibody titer in cell culture supernatant.
High Salt—High Reproducibility Analysis of antibody drug conjugates using hydrophobic interaction chromatography with the Agilent 1290 Infinity II Bio LC System
By removing iron from the LC flow path, the Agilent Infinity II Bio LC is perfectly suited for the high salt concentrations used in HIC-based drug-to-antibody ratio characterization.
Isolate and Reanalyze Pharma Impurities with the Agilent 1290 Infinity II Autoscale Preparative LC/MSD System
Learn about Agilent's Gly-X N-glycan sample preparation platform and available dye options for LC/FLD and LC/MS analysis of N-glycans from biotherapeutic glycoproteins.
Biophysical and Aggregate Characterization for the Development of Biologics
June 10th 2025This eBook explores how advanced particle analysis technologies are revolutionizing biologic drug development. It highlights the importance of accurately identifying and characterizing subvisible particles to ensure drug safety, stability, and regulatory compliance. Techniques like Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) are often used for their capabilities in detecting protein aggregates and degraded excipients such as polysorbates. Case studies and experimental results demonstrate how these tools provide high-throughput, low-volume analysis that enhances decision-making in formulation screening and manufacturing.
The Role of On-Demand Manufacturing and Derisking in Accelerating Early Clinical Trial Success
June 4th 2025Small pharmaceutical companies are constantly seeking innovative solutions to streamline early clinical trials. Adaptive clinical trials offer important benefits to sponsors and patients, both from a commercial and ethical standpoint. These trials offer flexibility and efficiency, especially in the early stages, where trial protocols can be adjusted based on interim data, such as introducing new doses or modifying participant sample size. However, adjusting manufacturing demand during an adaptive trial can be complicated, and strict regulatory requirements present significant challenges. On-demand manufacturing provides a robust solution, allowing for real-time supply and demand adjustments and improved trial flexibility. This paper explores how on-demand manufacturing meets the operational needs of adaptive trials and aligns with regulatory expectations.
Top 10 Cleanroom Problems That Can Be Prevented via Preventative Maintenance (May 2025)
May 16th 2025Cleanrooms require strict environmental control to maintain sterility, prevent contamination, and ensure seamless operations. Without a proactive preventative maintenance (PM) program, various issues can arise, leading to costly downtime, contamination risks, and operational inefficiencies. Below are ten common cleanroom problems that can be effectively mitigated through proper PM practices.
Optimizing cGMP Facility Design Space with a Hybrid Approach (May 2025)
May 16th 2025In this webcast, we review industry drivers and risks for capital construction, with a focus on cleanroom infrastructure, and discuss the goals of using a hybrid approach while demonstrating its application and benefits using real-world examples.
